Why Biomea Fusion, Inc.’s (BMEA) Stock Is Down 6.65%
As of Tuesday, October 13, Biomea Fusion, Inc.’s BMEA share price has dipped by 6.65%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Commentary & Analysis
Why Biomea Fusion, Inc.’s (BMEA) Stock Is Up 5.20%
As of Wednesday, October 07, Biomea Fusion, Inc.’s BMEA share price has surged by 5.20%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Biomea Fusion, Inc.’s (BMEA) Stock Is Up 5.16%
As of Wednesday, September 30, Biomea Fusion, Inc.’s BMEA share price has surged by 5.16%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Biomea Fusion, Inc.’s (BMEA) Stock Is Down 7.38%
As of Friday, September 25, Biomea Fusion, Inc.’s BMEA share price has dipped by 7.38%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Biomea Fusion, Inc.’s (BMEA) Stock Is Down 5.88%
As of Wednesday, September 23, Biomea Fusion, Inc.’s BMEA share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | BMEA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $91.3 | $224.8 | 21% |
|
| Shares Out (Mil) | 72.4 | 53.9 | 56% |
|
| Institutional Ownership | 86.0% | 93.1% | 54% |
|
| Float (Mil) | 67.7 | 40.6 | 53% |
|
| Beta | -0.30 | 0.95 | 3% |
|
| Avg Daily Volume (000s) | 1,974 | 632 | 81% |
|
| Price Change (52-week) |
(25.0%) | 47.3% | 32% |
|
| Growth | BMEA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.4% | na |
|
| Net Income (5yr) | (63.4%) | (10.2%) | 5% |
|
| EPS (5yr) | (18.6%) | 15.7% | 15 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.220) | ($0.842) | ($0.941) | |
| Month Ago EPS | ($0.220) | ($0.842) | ($0.941) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.270) | ($1.081) | ($1.103) | |
| Year/Year Chg | 91.3% | (28.8%) | (9.4%) | |
| Financials | BMEA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($33) | ($44) | 20% |
|
| EPS (TTM) | ($0.471) | ($1.600) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($47) | ($33) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $62 | $174 | 17% |
|
| Valuation | BMEA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.41 | 2.17 | 87% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BMEA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (59.1%) | (47.7%) | 10% |
|
| ROE | (164.1%) | (55.0%) | 5% |
|
| Liabilities to Assets | 67.1% | 29.4% | 63% |
|
| F-Score | 2 | 3 | 7% |
|
Biomea Fusion, Inc. did not pass any screens on 10/13/2026.
